



## | Mission

**We devote all our knowledge to  
serve people,  
enabling them to lead long and  
healthy lives**



# | Tradition, expertise, quality – 110 years history



Foundation of the legal predecessor of Egis by Swiss Dr. Albert Wander and Hungarian Sándor Balla Budapest



1913

1950

Commencement of API production Budapest

Start of injection production Budapest

1989



1995 - 2013

French Servier acquired 51% Stake in Egis  
Servier acquired 100% ownership of Egis

Egis launched Europe's first biosimilar monoclonal antibody medicine

Two technology-intensive investments finished in Körmend:  
- modernisation of the existing packaging infrastructure (1st phase)  
- Inauguration of a plant for finished oncology products with special manufacturing requirements

2021





# Egis premises in Hungary

2022/2023 business year



Modernising our premises - **410 million EUR** investment in 10 years

Budapest, Keresztúri út  
headquarters

**1240**  
colleagues



R&D  
HP development centre  
Active ingredient production

Budapest, Bökényföldi út  
site

**670**  
colleagues



R&D  
Finished product production  
(tableting/injection plants)  
Packaging  
Biosimilar secondary packaging

Budapest, Lehel utca  
site

**550**  
colleagues



Sales and marketing

Production site of  
Körmend

**590**  
colleagues



R&D  
Finished product production  
(tableting plant/ galenic plant)  
HP finished product production  
Packaging

# More than 30 million patients are treated yearly with Egis medicines



**835 tons**  
active ingredients/  
intermediates




**5.6 billion**  
tablets and capsules  
70% of the world population



**181 million**  
boxes of drugs sold ...

Los Angeles - Budapest – Tokyo  
...the length of the chain of boxes



# Egis in the world




Egis products reach  
**103 countries**

**€ 577.6 million**  
turnover in 2021/2022

**18 countries,**  
where Egis has  
its own marketing  
network

**4560**  
colleagues



Sales through our partners



Sales under the brand name Egis through our subsidiaries and representative offices, respectively



# Egis Vietnam in numbers



**23**

Years in Vietnam

**40**

Professionals

**28**

Products

**>1,2 MLN**

Patients treated

Patient number based on MAT2022 IQVIA market data

# Vertically integrated leading regional pharmaceutical company

2022/2023 business year



## Research and Development

- State-of-the-art research laboratories
- Highly potent active ingredients, value-added generics, branded generics

## Contract manufacturing and development

- active ingredients



## Active Ingredient and Finished Product Production

- Active ingredient synthesis
- Finished product formulation: tablets, capsules, injections, galenic forms
- Biosimilar: drug release testing secondary packaging
- Packaging



## Sales

- 22% domestic
- 78% export

- #8 position among Gx companies in the country
- Important role in local Pharma industry
  - EGIS gives the Vice-Chairman of the IQMED
- Increase presence in Vietnam
  - Double Egis sale in Vietnam in the next 3 years
  - Grow local organisation by 25%
- Continuous support of the local community





# | 9 Innovation Prizes

2022/2023 business year



◆ 1998 - „**Medicine of the year**”  
award for our potassium substitute

◆ **8 x Innovation Prize**  
**1 x Innovation Grand Prize**




# Regionally outstanding R&D investments\*

2022/2023 business year




17.1 billion HUF ( 45.2 million EUR/ 48.8 million USD)

2021/2022 business year, HUF billion  
\*based on the „Scoreboard 2022\_EU 1000” list, published as a part of The 2022 EU Industrial R&D Investment Scoreboard



# Main therapeutic areas


2022/2023 business year



2021/2022 business year, based on turnover of human drug sales

# Turnover by regions

2022/2023 business year





577.6 million EUR turnover

# Turnover data 2021/2022

2022/2023 business year



Turnover  
**577.6**  
million EUR



**ACCORDING TO THE  
NUMBER OF BOXES  
SOLD EGIS IN HUNGARY**

**1.** Largest supplier  
in Hungary

**10.7%** market  
share





# Turnover data

## 2021/2022

2022/2023 business year



### SALES REVENUE BY MAIN THERAPEUTIC AREAS




**149**  
active ingredients



**642**  
products



**181 million**  
sold boxes  
put next to each other:  
**Los Angeles-Budapest- Tokyo**  
distance



**4560**  
colleagues



**835 tons**  
active ingredients/  
intermediates



**5.6 billion**  
number of tablets  
and capsules  
manufactured



**3152**  
registrations

*Almost 70% of the  
world population*

# Egis products distributed in Vietnam (2025)



With these products we are open to be present in the Taiwanese market

INN	Formulation	Concentrate
Donepezil	tab.	5 mg & 10mg
Amlodipine	tab.	5 mg & 10mg
Clomiphene	tab.	50mg
Nifedipine	ret. fc. tab	20mg
Methyldopa	fc. tab	250mg
Metoprolol tartrate	tab.	25mg, 50mg & 100mg
Olanzapine	fc. tab.	10mg
Loratadine	tab.	10mg
Tofisopam	tab.	50mg
Ambroxol	syrup	0,3 g 1x100ml
Ambroxol	tab.	30mg
Lidocain	spray	10%
Allopurinol	tab.	200 mg & 300mg
Glyceryl trinitrate	aerosol	8 mg/g
Cilostazol	tab.	50 mg & 100mg
Bromhexine	tab.	8mg
Cyproheptadine	tab.	4mg
Promethazine	inj.	50 mg/ 2ml
Piracetam	fc. tab.	400 mg, 800mg &
Piracetam	inj	3 g/15 ml
Levocetirizine	tab.	5mg
Risperidone	fc. tab	1 mg & 2mg
Carvedilol	tab.	6,25 mg & 12,5mg
Levomepromazine	fc. tab.	25mg
Venlafaxine	retard cap.	75mg